A Novel Prognostic Model Predicts Outcomes in Non-Metastatic Nasopharyngeal Carcinoma Based on Inflammation, Nutrition, and Coagulation Signature

References

• Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64–80. doi:10.1016/S0140-6736(19)30956-0
   PubMed Web of Science ®Google Scholar
• Lai SZ, Liu MZ, Ma J. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys. 2011;80(3):661–668. doi:10.1016/j.ijrobp.2010.03.024
   PubMed Web of Science ®Google Scholar
• Zhang MX, Hong MH, Chen MY. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: a 10-year experience with a large cohort and long follow-up. Eur J Cancer. 2015;51(17):2587–2595. doi:10.1016/j.ejca.2015.08.006
   PubMed Web of Science ®Google Scholar
• Tang LL, Sun Y, Ma J. Validation of the 8th Edition of the UICC/AJCC Staging System for Nasopharyngeal Carcinoma From Endemic Areas in the Intensity-Modulated Radiotherapy Era. J Natl Compr Canc Netw. 2017;15(7):913–919. doi:10.6004/jnccn.2017.0121
   PubMed Web of Science ®Google Scholar
• Zhong L, Tang L, Tian J. A deep learning-based radiomic nomogram for prognosis and treatment decision in advanced nasopharyngeal carcinoma: a multicentre study. EBioMedicine. 2021;70:103522. doi:10.1016/j.ebiom.2021.103522
   PubMed Web of Science ®Google Scholar
• Wu Z, Weng D, Li G. Quantitative proteome analysis of overexpressed Cripto-1 tumor cell reveals 14-3-3gamma as a novel biomarker in nasopharyngeal carcinoma. J Proteomics. 2013;83:26–36. doi:10.1016/j.jprot.2013.03.001
   PubMed Web of Science ®Google Scholar
• Liu SL, Sun XS, Chen QY, et al. Development and validation of a transcriptomics-based gene signature to predict distant metastasis and guide induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Eur J Cancer. 2022;163:26–34. doi:10.1016/j.ejca.2021.12.017
   PubMed Web of Science ®Google Scholar
• Li XY, Luo DH, Guo L, et al. Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: a Phase II Randomized Noninferiority Trial. J Clin Oncol. 2022;40(11):1163–1173. doi:10.1200/JCO.21.01467
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–444. doi:10.1038/nature07205
   PubMed Web of Science ®Google Scholar
• Arends J, Baracos V, Bertz H, et al. ESPEN expert group recommendations for action against cancer-related malnutrition. Clinical Nutrition. 2017;36(5):1187–1196. doi:10.1016/j.clnu.2017.06.017
   PubMed Web of Science ®Google Scholar
• Bauer AT, Gorzelanny C, Gebhardt C, Pantel K, Schneider SW. Interplay between coagulation and inflammation in cancer: limitations and therapeutic opportunities. Cancer Treat Rev. 2022;102. doi:10.1016/j.ctrv.2021.102322
   Web of Science ®Google Scholar
• Miao J, Xiao W, Wang L, et al. The value of the Prognostic Nutritional Index (PNI) in predicting outcomes and guiding the treatment strategy of nasopharyngeal carcinoma (NPC) patients receiving intensity-modulated radiotherapy (IMRT) with or without chemotherapy. J Cancer Res Clin Oncol. 2017;143(7):1263–1273. doi:10.1007/s00432-017-2360-3
   PubMed Web of Science ®Google Scholar
• Kucukarda A, Erdogan B, Gokyer A, et al. Prognostic nutritional index and its dynamics after curative treatment are independent prognostic factors on survival in non-metastatic nasopharyngeal carcinoma. Support Care Cancer. 2022;30(3):2131–2139. doi:10.1007/s00520-021-06627-6
   PubMed Web of Science ®Google Scholar
• Li G, Gao J, Liu ZG, et al. Influence of pretreatment ideal body weight percentile and albumin on prognosis of nasopharyngeal carcinoma: long-term outcomes of 512 patients from a single institution. Head Neck. 2014;36(5):660–666. doi:10.1002/hed.23357
   PubMed Web of Science ®Google Scholar
• Tang LQ, Zeng MS, Mai HQ. The impact of plasma Epstein-Barr virus DNA and fibrinogen on nasopharyngeal carcinoma prognosis: an observational study. Br J Cancer. 2014;111(6):1102–1111. doi:10.1038/bjc.2014.393
   PubMed Web of Science ®Google Scholar
• S-S H, L-X L, Chen Y. Plasma Fibrinogen Correlates with Metastasis and is Associated with Prognosis in Human Nasopharyngeal Carcinoma. J Cancer. 2017;8(3):403–409. doi:10.7150/jca.17028
   PubMed Web of Science ®Google Scholar
• Jae-Keun CH-SJ, Chan Ahn Y. Development and external validation of nomograms predictive of response to radiation therapy and overall survival in nasopharyngeal cancer patients. Eur J Cancer. 2015;51(10):1303–1311. doi:10.1016/j.ejca.2015.04.003
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu Q, Ma J. Nomogram to predict the benefit of additional induction chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: analysis of a multicenter, Phase III randomized trial. Radiother Oncol. 2018;129(1):18–22. doi:10.1016/j.radonc.2017.12.002
   PubMed Web of Science ®Google Scholar
• Miao S, Lei H, Li X, et al. Development and validation of a risk prediction model for overall survival in patients with nasopharyngeal carcinoma: a prospective cohort study in China. Cancer Cell Int. 2022;22(1):360. doi:10.1186/s12935-022-02776-8
   PubMed Web of Science ®Google Scholar
• Pan JJ, Ng WT, Zong JF, et al. Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. Cancer. 2016;122(21):3307–3315. doi:10.1002/cncr.30198
   PubMed Web of Science ®Google Scholar
• Xu C, Sun Y, Ma J. Establishing and applying nomograms based on the 8th edition of the UICC/AJCC staging system to select patients with nasopharyngeal carcinoma who benefit from induction chemotherapy plus concurrent chemoradiotherapy. Oral Oncol. 2017;69:99–107. doi:10.1016/j.oraloncology.2017.04.015
   PubMed Web of Science ®Google Scholar
• Zhang LL, Li YY, Shao JY. Development of a Nomogram Model for Treatment of Nonmetastatic Nasopharyngeal Carcinoma. JAMA Netw Open. 2020;3(12):e2029882. doi:10.1001/jamanetworkopen.2020.29882
   PubMed Web of Science ®Google Scholar
• Mao JR, Lan KQ, Liu SL, et al. Can the prognosis of individual patients with nasopharyngeal carcinoma be predicted using a routine blood test at admission? Radiother Oncol. 2023;179:109445. doi:10.1016/j.radonc.2022.109445
   PubMed Web of Science ®Google Scholar
• Tang LQ, Mai HQ, Zeng MS. Establishment and Validation of Prognostic Nomograms for Endemic Nasopharyngeal Carcinoma. J Natl Cancer Inst. 2016;108(1):67.
   Google Scholar
• Lu ZJ, Liu LT, Sun XS, et al. Establishment and validation of a prognostic nomogram to predict early metastasis in nasopharyngeal carcinoma patients within six months after radiotherapy and to guide intensive treatment. Radiother Oncol. 2021;162:202–211. doi:10.1016/j.radonc.2021.03.035
   PubMed Web of Science ®Google Scholar
• Li J, Chen S, Peng S, et al. Prognostic nomogram for patients with Nasopharyngeal Carcinoma incorporating hematological biomarkers and clinical characteristics. Int J Biol Sci. 2018;14(5):549–556. doi:10.7150/ijbs.24374
   PubMed Web of Science ®Google Scholar
• Lv SH, Li WZ, Liang H, Liu GY, Xia WX, Xiang YQ. Prognostic and Predictive Value of Circulating Inflammation Signature in Non-Metastatic Nasopharyngeal Carcinoma: potential Role for Individualized Induction Chemotherapy. J Inflamm Res. 2021;14:2225–2237. doi:10.2147/JIR.S310017
   PubMed Web of Science ®Google Scholar
• Lai C, Chen S, Zhou L. A novel prognostic model predicts overall survival in patients with nasopharyngeal carcinoma based on clinical features and blood biomarkers. Cancer Med. 2021;10(11):3511–3523. doi:10.1002/cam4.3839
   PubMed Web of Science ®Google Scholar
• Zeng L, Gong XC, Li JG. Risk factors and distribution features of level IB lymph nodes metastasis in nasopharyngeal carcinoma. Auris Nasus Larynx. 2019;46(3):457–464. doi:10.1016/j.anl.2018.10.012
   PubMed Web of Science ®Google Scholar
• Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med. 1997;16(4):385–395. doi:10.1002/(sici)1097-0258(19970228)16:4<385::aid-sim380>3.0.co;2-3
   PubMed Web of Science ®Google Scholar
• Camp MD-F RL, Rimm DL. X-tile a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004. doi:10.1158/1078-0432.CCR-04-0713
   Web of Science ®Google Scholar
• Yu W, Jiang X, Jiang Y. Preoperative albumin-to-fibrinogen ratio predicts chemotherapy resistance and prognosis in patients with advanced epithelial ovarian cancer. J Ovarian Res. 2019;12(1):88. doi:10.1186/s13048-019-0563-8
   PubMedGoogle Scholar
• Zhang J, Zhang M, Xu M. Development and validation of a prognostic model based on the albumin-to-fibrinogen ratio (AFR) and gamma-glutamyl transpeptidase-to-platelet ratio (GPR) in hepatocellular carcinoma patients. Clin Chim Acta. 2020;511:107–116. doi:10.1016/j.cca.2020.09.038
   PubMed Web of Science ®Google Scholar
• You X, Chen J, Shen H. Preoperative albumin-to-fibrinogen ratio predicts severe postoperative complications in elderly gastric cancer subjects after radical laparoscopic gastrectomy. BMC Cancer. 2019;19(1):931. doi:10.1186/s12885-019-6143-x
   PubMed Web of Science ®Google Scholar
• Ying HQ, Chen W, Xiong CF, Wang Y, Li XJ, Cheng XX. Quantification of fibrinogen-to-pre-albumin ratio provides an integrating parameter for differential diagnosis and risk stratification of early-stage colorectal cancer. Cancer Cell Int. 2022;22(1):137. doi:10.1186/s12935-022-02532-y
   PubMed Web of Science ®Google Scholar
• Li SQ, Jiang YH, Lin J, et al. Albumin-to-fibrinogen ratio as a promising biomarker to predict clinical outcome of non-small cell lung cancer individuals. Cancer Med. 2018;7(4):1221–1231. doi:10.1002/cam4.1428
   PubMed Web of Science ®Google Scholar
• Sun Y, Liu MZ, Ma J. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a Phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016;17(11):1509–1520. doi:10.1016/S1470-2045(16)30410-7
   PubMed Web of Science ®Google Scholar
• Cao SM, Guo X, Hong MH. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase III multicentre randomised controlled trial. Eur J Cancer. 2017;75:14–23. doi:10.1016/j.ejca.2016.12.039
   PubMed Web of Science ®Google Scholar
• Zhang Y, Sun Y, Ma J. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. N Engl J Med. 2019;381(12):1124–1135. doi:10.1056/NEJMoa1905287
   PubMed Web of Science ®Google Scholar
• Lei Y, Liu N, Ma J. A Gene-Expression Predictor for Efficacy of Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma. J Natl Cancer Inst. 2021;113(4):471–480. doi:10.1093/jnci/djaa100
   PubMedGoogle Scholar
• Liu SL, Bian LJ, Liu ZX, et al. Development and validation of the immune signature to predict distant metastasis in patients with nasopharyngeal carcinoma. J Immunother Cancer. 2020;8(1). doi:10.1136/jitc-2019-000205
   Web of Science ®Google Scholar
• Tang LL, Guo R, Zhang N, et al. Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: a Randomized Clinical Trial. JAMA. 2022;328(8):728–736. doi:10.1001/jama.2022.13997
   PubMed Web of Science ®Google Scholar
• Xu C, Zhang S, W-F L, et al. Selection and Validation of Induction Chemotherapy Beneficiaries Among Patients With T3N0, T3N1, T4N0 Nasopharyngeal Carcinoma Using Epstein-Barr Virus DNA: a Joint Analysis of Real-World and Clinical Trial Data. Front Oncol. 2019:9. doi:10.3389/fonc.2019.01343
   PubMed Web of Science ®Google Scholar
• Sun Y, Tang -L-L, Chen L, et al. Promising treatment outcomes of intensity-modulated radiation therapy for nasopharyngeal carcinoma patients with N0 disease according to the seventh edition of the AJCC staging system. BMC Cancer. 2012;12(1). doi:10.1186/1471-2407-12-68
   Google Scholar
• Huang C-L, Guo R, J-Y L, et al. Nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: clinical outcomes and patterns of failure among subsets of 8th AJCC stage IVa. Eur Radiol. 2019;30(2):816–822. doi:10.1007/s00330-019-06500-5
   PubMed Web of Science ®Google Scholar
• Chen X, Zhu X, Liang Z, et al. Long-term outcomes of neoadjuvant chemotherapy followed by concurrent chemoradiotherapy (CCRT) vs CCRT alone for nasopharyngeal carcinoma in the era of intensity-modulated radiation therapy using propensity score matching method. Onco Targets Ther. 2017;10:2909–2921. doi:10.2147/OTT.S135590
   PubMed Web of Science ®Google Scholar
• Wu LR, Jiang XS, Song X, et al. Comparing the efficacy of induction-concurrent with concurrent-adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: a propensity score matching analysis. Oncotarget. 2017;8(45):79953–79963. doi:10.18632/oncotarget.20389
   PubMedGoogle Scholar